Background

Proprietary Migraine Botulinum Toxin for ObA

Objectives

Methods

All analyses were conducted using integrated medical and pharmacy administrative claims data from a large, national employer-based, commercial or Medicare Advantage population. Proprietary Migraine Botulinum Toxin Use and Expenditure in the Botulinum Toxin Class

Proportion of Migraine ObA Use and Spending in the Botulinum Toxin Class (Figures 1 and 2)

Results

Limitations

Conclusions

References